Navigation Links
FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS
Date:11/30/2009

to ten per million, or approximately 2,000 to 5,000 patients in the E.U. and 1,200 to 3,100 patients in the U.S. Approximately 50 percent of LEMS patients diagnosed have small cell lung cancer.

Patients with LEMS typically present with fatigue, muscle pain and stiffness. The weakness is generally more marked in the proximal muscles particularly of the legs and trunk. Other problems include reduced reflexes, drooping of the eyelids, facial weakness and problems with swallowing. Patients often report a dry mouth, impotence, constipation and feelings of light headedness on standing. On occasion these problems can be life threatening when the weakness involves respiratory muscles. A diagnosis of LEMS is generally made on the basis of clinical symptoms, electromyographic testing and the presence of autoantibodies against voltage gated calcium channels.

Current treatment of LEMS can consist of strategies directed at the underlying malignancy if one is present. Unfortunately, therapy of small cell lung cancer is limited and outcomes are generally poor. Immunosuppressive agents have been tried but success is limited by toxicity, and difficulty administering the regimens. A mainstay of therapy has been 3,4-DAP but its use in practice has been limited by the drug's availability. This problem will be addressed by the introduction of BioMarin's product.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan®
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Mirus Bio Awarded Grants & Contracts of Over $5 Million
2. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. NIH grants $750,000 to develop device to determine temperature of neonates brain
5. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
6. Radius Grants Major Pharmaceutical Company Exclusive Option to License BA058 for Osteoporosis
7. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
8. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
9. NASDAQ Panel Grants Merge Technologies Additional Time to Regain Compliance
10. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
11. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... The severe flooding that devastated a wide swath of ... the bridges, roads and other infrastructure had been upgraded ... University of Colorado Denver. , "People need to understand ... PhD, associate professor of structural engineering at the CU ... author the study. "There is an assumption that a ...
(Date:10/27/2014)... Kalorama Information says that PCR is demonstrating ... the United States and is the ... said the FDA,s Emergency Use Authorization (EUA) to authorize the ... detection of the Ebola virus was an indication that ... the IVD industry and its biennial survey on diagnostics ...
(Date:10/27/2014)... 2014 Pressure BioSciences, Inc. (OTCQB: PBIO) ... the development and sale of high pressure-based sample ... today announced that Professor Ruedi Aebersold ... reproducible, and robust method to allow – for ... on small needle biopsy samples by mass spectrometry ...
(Date:10/25/2014)... The report “Adipic Acid Market by ... Global Trends & Forecast to 2019” report analyzes ... drivers, opportunities, and trends in different regions. , ... spread through 217 slides and in-depth TOC on ... to 2019”., http://www.marketsandmarkets.com/Market-Reports/adipic-acid-269.html , Early buyers will ...
Breaking Biology Technology:CU Denver study says upgrading infrastructure could reduce flood damage 2Kalorama: PCR The Go-to Test in Ebola Fight 2Kalorama: PCR The Go-to Test in Ebola Fight 3Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 2Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 3Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 4Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 5Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 2Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 3Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 4
... that going from a positive to a negative is a ... scientists from the National Institute of Standards and Technology (NIST) ... extended the reach of their novel microfluidic system for analyzing ... how the system, meant to analyze real-world, crude mixtures such ...
... help resolve the public debate over America,s future light source ... compact fluorescent lamp. It could be neither. ... new breed of light emitting diode, or LED, that conjures ... an article in the current online issue of the journal ...
... Ariz., Aug. 31, 2011 SynCardia Systems, Inc. ( www.syncardia.com ... today that it has launched company pages on Facebook ... to educate a larger audience about the world,s only FDA, ... have been more than 950 implants of the Total Artificial ...
Cached Biology Technology:Researchers expand capabilities of miniature analyzer for complex samples 2Manufacturing method paves way for commercially viable quantum dot-based LEDs 2Manufacturing method paves way for commercially viable quantum dot-based LEDs 3SynCardia Goes Social on Facebook, Twitter and LinkedIn 2SynCardia Goes Social on Facebook, Twitter and LinkedIn 3SynCardia Goes Social on Facebook, Twitter and LinkedIn 4
(Date:10/28/2014)... of Health (NIH) announced awards to expand the ... National Center for Advancing Translational Sciences (ORDR-NCATS) collaborative ... the network, physician scientists at 22 consortia will ... clinical research and investigate new treatments for patients ... by $29 million in fiscal 2014 funding from ...
(Date:10/27/2014)... researchers have delivered a scientific one-two punch with a ... self-assemble via their sticky ends. , Collagen is the ... bone and the fibrous tissues that support cells and ... better synthetic collagen for tissue engineering and cosmetic and ... has been studying synthetic collagen for a decade, teasing ...
(Date:10/27/2014)... 27, 2014) — Recent breakthroughs may pave the ... infected by parasitic helminths. These flatworms, including tapeworms ... and blood flukes (schistosomes), infect more than 300 ... life years lost due to chronic illness and ... , professor of microbiology, immunology, and tropical medicine, ...
Breaking Biology News(10 mins):NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 2NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 3'Sticky' ends start synthetic collagen growth 2'Sticky' ends start synthetic collagen growth 3GW researcher adapting breakthrough technologies to combat parasitic worm infections 2
... of the brain are over-stimulated and this leads to ... this process was finally shown last year to be ... stroke. But very few targets for drugs to block ... detailed study, researchers have discovered a previously missing link ...
... an evolutionary geneticist at Fred Hutchinson Cancer Research Center who ... with opposing functions that drives evolutionary change has been ... is among 27 of the nation,s top biomedical scientists to ... more than 1,100 applicants. , "HHMI has a very ...
... Solanaceaea flowering plant family with some species producing foods ... effect against Parkinson,s disease. The study appearing today in ... American Neurological Association and Child Neurology Society, suggests that ... nicotine, such as peppers and tomatoes, may reduce risk ...
Cached Biology News:Researchers discover a missing link in signals contributing to neurodegeneration 2Fred Hutch evolutionary geneticist Harmit Malik selected as an HHMI investigator 2Fred Hutch evolutionary geneticist Harmit Malik selected as an HHMI investigator 3Could eating peppers prevent Parkinson's? 2
Rabbit anti MMP-13, Hinge Region MMP-13 Hinge Region...
Mouse monoclonal [SIT-01] to SIT ( Abpromise for all tested applications). entrezGeneID: 27240 SwissProtID: Q9Y3P8...
Anti-MMP-25 (Membrane-type MMP-6, Mt6MMP), hinge region; rabbit host...
D4-GDI rabbit polyclonal antibody...
Biology Products: